Based on this YouTube video's total view count of 732K views and industry-standard rates, the estimated total earning is $513 - $1.46K through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore I’m a Pathologist. Retatrutide is NOT Ozempic. It’s Biological Overdrive. with 732,975 views, 19,749 likes, and 2,913 comments. Experience the impact of this video content that has captured audience attention.

Imagine a molecule so powerful it doesn't just silence your hunger, it can "power-wash" 80% of the fat out of your liver in a matter of months (based on the studies published). We’ve seen Ozempic as a GLP-1 agonist and Mounjaro as a dual GLP/GIP receptor agonist. But while the world was distracted by the side effects of the first generation, a "Triple-Agonist" was being engineered. It’s called Retatrutide. In this video, I’m tallying the "biological price tag" of Retatrutide that often stays buried in the medical literature. As a Triple Board-Certified Physician, Pathologist, I’ve spent the last few weeks dismantling the TRIUMPH Phase 3 clinical data to separate the marketing noise from the cellular reality. We explore the "Glucagon Paradox," the risk of heart redlining (tachycardia), muscle wasting (sarcopenia), and how to actively mitigate these risks if you and your doctor decide this is the right path for you. Hit subscribe and join me as we decode the story your tissue is telling. 🔬 Stay curious, take care of your cells and stay uninflamed, Amin Hedayat, MD 📚 PEER-REVIEWED REFERENCES & CLINICAL DATA: Primary Retatrutide (LY3437943) Clinical Trials: Obesity & Weight Loss (TRIUMPH-1): Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine (NEJM). (DOI: 10.1056/NEJMoa2301972). Type 2 Diabetes (TRANSCEND): Rosenstock J, et al. "Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled phase 2 trial." The Lancet. Liver Fat & MASLD Resolution: Sanyal AJ, et al. "Retatrutide Phase 2 Data on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)." Presented at the American Association for the Study of Liver Diseases (AASLD). (Confirmed 80%+ liver fat reduction). Mechanism of Action & Physiology: The Triple Agonist Architecture: Coskun T, et al. "LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist: Differential effects on body weight and energy expenditure." Cell Metabolism. Glucagon & Thermogenesis: Knerr PJ, et al. "Next-generation multi-agonist peptides for the treatment of metabolic diseases." Nature Reviews Drug Discovery. Cardiac Impact & SA Node: D’Alessio D, et al. "The role of glucagon receptors in cardiac function and heart rate variability." Journal of Clinical Investigation. Muscle Wasting & Sarcopenia Data: Lean Mass Loss in Incretin Therapy: Heymsfield SB, et al. "Body composition changes during weight loss with GLP-1 receptor agonists." Obesity Reviews. Protein Mitigation Strategies: "The role of leucine and high-quality protein in preserving muscle mass during calorie restriction." Nutrients Journal (MDPI). ClinicalTrials.gov: NCT05882045 (TRIUMPH-1) and NCT05929079 (TRIUMPH-3). DISCLAIMER: This video is for educational and informational purposes only and does not constitute individual medical advice. Dr. Hedayat is an MD but he is not your personal physician. Always seek the advice of your own medical care team regarding any medications, clinical trials, or health routine changes. At publication of this video, retatrutide is currently an investigational drug and is not FDA-approved for public use as of this recording. ⏱️ CHAPTERS: 0:00 - The "Power-Wash" Molecule 2:25 - The FDA & Gray Market Warning 3:56 - Why Dieting Fails: Hardware vs. Software 5:19 - The Hypothalamus: Metabolism's Air Traffic Control 6:23 - The "Triple-Lock" Master Key & Glucagon Paradox 8:02 - Power-Washing the Liver (MASLD Recovery) 9:40 - The Heart Price Tag: Tachycardia Risks 10:49 - Muscle Wasting & Sarcopenia 11:51 - Anhedonia: The "Grayscale" Life 12:24 - Risk Mitigation Protocols 14:57 - The Pathologist's Verdict Current Trial Status: #Retatrutide #Mounjaro #Ozempic #WeightLoss #Pathology #MetabolicHealth #FattyLiver #Sarcopenia #Tachycardia #DrAminHedayat #TRIUMPHtrials #Biohacking #GLP1 #MedicalScience #LiverHealth

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.